Galderma stock faces CFO transition ahead of December vote
Published on 11/13/2026 at 12:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGovernance changes set December vote
- Luigi La Corte will leave Galderma after a transition period, with succession details still pending.
- Shareholders will vote on two proposed directors and a larger board at the December 3 extraordinary meeting.
- Galderma says the appointments support its Integrated Dermatology Strategy and longer-term growth ambitions.
Galderma Group AG is preparing for a finance leadership transition and a shareholder vote on board changes. In a November 2 company announcement, Galderma said Chief Financial Officer Luigi La Corte had decided to leave for a significant new opportunity.
La Corte will continue to fulfil his CFO responsibilities during the transition period, which Galderma said should support business continuity and a smooth handover. The company did not provide a successor or a transition timetable in the announcement, leaving the next steps in the finance function open.
Board proposals go to shareholders
Galderma's board has proposed Rosalind Brewer and Petra Rumpf as new directors. The company described both candidates as bringing leadership and governance experience across consumer-facing businesses, healthcare, medtech and life sciences.
Sherilyn McCoy is set to leave the board after seven years because of conflicting obligations. The proposals would raise the board's maximum size from 10 to 11 members, elect Brewer and Rumpf until the next Annual General Meeting and put Brewer forward for individual election to the Compensation Committee.
The changes are subject to a virtual Extraordinary General Meeting on Thursday, December 3, 2026, at 14:00 CET. For investors, the meeting is the next defined governance event, while the CFO succession remains a separate execution issue until Galderma provides further details.
Leadership change meets growth strategy
Chief Executive Officer Flemming Ornskov said the company remains focused on its Integrated Dermatology Strategy and that the proposed appointments would add expertise and perspectives for Galderma's next phase of growth. The group operates across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology.
Galderma stock traded at 210.00 euros on Lang & Schwarz at 11:58 CET on Friday, November 13.
Galderma Group AG at a glance
- Company: Galderma Group AG
- ISIN: CH1335392721
- Ticker: GALD
- Home exchange: SIX Swiss Exchange
- Lang & Schwarz quote: 210.00 euros at 11:58 CET on Friday, November 13, 2026
In the broader Swiss market, the SMI provides the relevant benchmark for investors.
